Merck & Co 30 year tipped to bring wave of copycats

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Corporate Bonds

Merck & Co 30 year tipped to bring wave of copycats

Mike Turner
May 16, 2024 04:55 pm
Pills of the drug Molnupiravir in a blister package. Molnupiravir was developed by Merck & Co and is an antiviral Covid-19 therapy. Selective focus

‘Definitely more’ corporates seeking ultra-long maturities

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Corporate BondsHigh grade and crossover bondsUnited StatesEuroEurope
MT
Mike Turner
Corporate Debt Editor
Contact
Gift this article